Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 15, 2024 4:47pm
131 Views
Post# 36267072

RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

RE:CellPress: Emerging Field of OV Based Cancer ImmunotherapyCombination therapy with PD-L! immune checkpoint inhibitors is beginning to demonstrate extended patient survival.

October 15, 2024 - It's quite the turn of events for Jazz Pharmaceuticals’ Zepzelca, - once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer (ES-SCLC).

Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo, Jazz said Tuesday.

The addition of Zepzelca delayed disease progression and extended survival, leading to a statistically significant improvement in both overall survival and progression-free survival by independent review in the phase 3 IMforte trial.

While keeping Zepzelca’s accelerated approval in place, the FDA accepted Jazz’s proposal of two new trials to confirm Zepzelca’s efficacy, and one of them is IMforte. The trial had previously carried a primary completion date in September 2025.


https://www.fiercepharma.com/pharma/jazzs-almost-withdrawn-lung-cancer-drug-zepzelca-extends-life-top-roches-tecentriq

<< Previous
Bullboard Posts
Next >>